SCHEMBL6790238

SCHEMBL6790238

C/C(=C/C(=O)Nc1cc(NS(=O)(=O)c2ccccc2)ccc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.67
GPR27 Q9NS67 1/20 0.51
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
AKR1C3 P42330 1/20 0.50
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 1/20 0.48
PLA2G7 Q13093 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786986 0.92 TERT (0.67) TERTGPR27LMNASMN1; SMN2AKR1C3
SCHEMBL6786322 0.92 TERT (0.56) TERTGPR27LMNASMN1; SMN2AKR1C3
SCHEMBL6786381 0.90 TERT (0.69) TERTGPR27LMNASMN1; SMN2AKR1C3
SCHEMBL6787585 0.85 TERT (0.73) TERTAKR1C3MEN1KMT2AALDH1A1
SCHEMBL6784867 0.83 TERT (0.55) TERTGPR27LMNASMN1; SMN2AKR1C3
SCHEMBL6783732 0.83 TERT (0.85) TERTAKR1C3KDM4E
SCHEMBL6791675 0.83 TERT (0.71) TERTALDH1A1KDM4EMAPT
SCHEMBL6785319 0.83 TERT (0.71) TERTLMNAMEN1KMT2AALDH1A1
SCHEMBL6785193 0.82 TERT (0.69) TERTGPR27LMNASMN1; SMN2AKR1C3
SCHEMBL6785060 0.81 TERT (0.68) TERTMEN1KMT2AKDM4EHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885GPR27 2546/4885LMNA 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.